[go: up one dir, main page]

MX2018012814A - Métodos para modular selectivamente la actividad de distintos sub-tipos de células. - Google Patents

Métodos para modular selectivamente la actividad de distintos sub-tipos de células.

Info

Publication number
MX2018012814A
MX2018012814A MX2018012814A MX2018012814A MX2018012814A MX 2018012814 A MX2018012814 A MX 2018012814A MX 2018012814 A MX2018012814 A MX 2018012814A MX 2018012814 A MX2018012814 A MX 2018012814A MX 2018012814 A MX2018012814 A MX 2018012814A
Authority
MX
Mexico
Prior art keywords
cells
activity
selectively modulate
particles
types
Prior art date
Application number
MX2018012814A
Other languages
English (en)
Inventor
Costa Fejoz Caroline
Verhoeyen Els
Loïc COSSET François
Bender Ruben
Buchholz Christian
Zhou Qi
Original Assignee
Ecole Normale Superieure Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Normale Superieure Lyon filed Critical Ecole Normale Superieure Lyon
Publication of MX2018012814A publication Critical patent/MX2018012814A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4237—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)

Abstract

La presente invención se relaciona con partículas similares retrovirus de seudo-tipo o vectores retrovirales que comprenden tanto glicoproteínas envolventes derivadas de un virus de la familia Paramyxoviridae fusionadas con un dominio dirigido a célula y fusionadas con un dominio funcional; la presente invención también se relaciona con el uso de dichas partículas de similares a retrovirus de seudo-tipo o vectores retrovirales para modular de manera selectiva la actividad de sub-conjuntos específicos de células, en particular de células inmunitarias específicas; estas partículas similares a retrovirus de seudo-tipo o vectores retrovirales son particularmente útiles para terapia génica, terapia inmunitaria y/o vacunación.
MX2018012814A 2016-04-21 2017-04-20 Métodos para modular selectivamente la actividad de distintos sub-tipos de células. MX2018012814A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305468.7A EP3235908A1 (en) 2016-04-21 2016-04-21 Methods for selectively modulating the activity of distinct subtypes of cells
PCT/EP2017/059435 WO2017182585A1 (en) 2016-04-21 2017-04-20 Methods for selectively modulating the activity of distinct subtypes of cells

Publications (1)

Publication Number Publication Date
MX2018012814A true MX2018012814A (es) 2019-06-20

Family

ID=56008561

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012814A MX2018012814A (es) 2016-04-21 2017-04-20 Métodos para modular selectivamente la actividad de distintos sub-tipos de células.
MX2023006961A MX2023006961A (es) 2016-04-21 2018-10-19 Metodos para modular selectivamente la actividad de distintos subtipos de celulas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006961A MX2023006961A (es) 2016-04-21 2018-10-19 Metodos para modular selectivamente la actividad de distintos subtipos de celulas.

Country Status (14)

Country Link
US (2) US11608509B2 (es)
EP (3) EP3235908A1 (es)
JP (5) JP7412885B2 (es)
KR (2) KR20250035028A (es)
CN (2) CN117126817A (es)
AU (3) AU2017253364B2 (es)
CA (1) CA3021549A1 (es)
EA (1) EA201892369A1 (es)
ES (1) ES2961976T3 (es)
IL (2) IL262458B2 (es)
MX (2) MX2018012814A (es)
SG (1) SG11201809164TA (es)
WO (1) WO2017182585A1 (es)
ZA (1) ZA201807161B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
EP3622079B1 (en) 2017-05-08 2025-08-20 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
JP7568513B2 (ja) * 2018-05-15 2024-10-16 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド フソソーム組成物およびその使用
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
KR20210043574A (ko) 2018-07-09 2021-04-21 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소좀 조성물 및 이의 용도
KR20210131991A (ko) 2018-11-14 2021-11-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 구획-특이적 카고 전달을 위한 조성물 및 방법
AU2019380517A1 (en) * 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
AU2019378881A1 (en) * 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for CNS delivery
WO2020102503A2 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
CN110004181B (zh) * 2019-03-20 2022-10-11 东北农业大学 一种附加型CRISPR/Cas9表达载体及其构建方法与应用
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CA3140115A1 (en) 2019-05-23 2020-11-26 Massachusetts Institute Of Technology Ligand discovery and gene delivery via retroviral surface display
EP3982989A4 (en) 2019-06-13 2023-07-19 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US20220333132A1 (en) 2019-09-03 2022-10-20 Sana Blotechnology, Inc. Cd24-associated particles and related methods and uses thereof
CA3152414A1 (en) 2019-09-26 2021-04-01 President And Fellows Of Harvard College Minimal arrestin domain containing protein 1(arrdc1) constructs
CN110904116B (zh) * 2019-10-24 2022-12-09 中国科学院遗传与发育生物学研究所 植物phl3基因在调控植物种子大小、干重和脂肪酸积累中的应用
AU2021236226A1 (en) 2020-03-11 2022-09-15 The Trustees Of The University Of Pennsylvania Methods and composition for gene delivery using an engineered viral particle
EP4127144A1 (en) * 2020-03-31 2023-02-08 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
EP4182447A4 (en) * 2020-07-14 2024-10-23 Ichilov Tech Ltd. PSEUDOTYPED VIRUSES WITH CONFIGURATION FOR EXPRESSION OF CAR IN T CELLS
KR20230043151A (ko) 2020-07-24 2023-03-30 더 제너럴 하스피탈 코포레이션 증강된 바이러스-유사 입자 및 세포에의 전달을 위한 그의 사용 방법
EP3964585A1 (en) * 2020-09-03 2022-03-09 Miltenyi Biotec B.V. & Co. KG Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
TW202242121A (zh) * 2021-01-11 2022-11-01 美商薩那生物科技公司 靶向cd8之病毒載體之用途
MX2023009910A (es) 2021-02-26 2023-11-09 Kelonia Therapeutics Inc Vectores lentivirales dirigidos a los linfocitos.
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
WO2022216915A1 (en) * 2021-04-08 2022-10-13 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
WO2022251712A1 (en) 2021-05-28 2022-12-01 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
US20250051797A1 (en) * 2021-12-13 2025-02-13 Interius Biotherapeutics, Inc. Engineered viral particles and uses of the same
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
EP4448549A2 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
EP4493157A2 (en) * 2022-03-11 2025-01-22 President and Fellows of Harvard College Targeted delivery of armms
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20250340899A1 (en) * 2022-04-25 2025-11-06 Tokiwa-Bio Inc. Rna virus-derived chimeric envelope protein and rna virus vector having same
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024254346A1 (en) * 2023-06-07 2024-12-12 The Broad Institute, Inc. Engineered viral like particles (evlps) for the selective transduction of target cells
CN116515865B (zh) * 2023-06-19 2025-11-14 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的尼帕病毒病疫苗
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
CN117659133B (zh) * 2023-12-06 2024-09-20 南京鼓楼医院 间皮素靶向结合蛋白、其编码核酸以及用途
WO2025176853A1 (en) * 2024-02-22 2025-08-28 Miltenyi Biotec B.V. & Co. KG Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN118108809B (zh) * 2024-03-15 2025-02-28 西湖实验室(生命科学和生物医学浙江省实验室) 一种跨膜荧光蛋白、水溶荧光蛋白及其用途
KR102900650B1 (ko) * 2024-08-01 2025-12-19 대한민국 니파바이러스 g 당단백질 유래 에피토프를 포함하는 펩타이드 및 이를 포함하는 백신 조성물
CN120209100B (zh) * 2025-03-28 2025-09-05 河北金要生物科技有限公司 一种表达mIL21和4-1BBL的病毒样颗粒及其在体外扩增NK细胞中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69938931D1 (de) 1998-09-23 2008-07-31 Inst Virologie Teilrechtsfaehi Retrovirale partikel, geschützt gegen komplementvermittelte lyse
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
AU2001251138A1 (en) 2000-03-31 2001-10-15 Mayo Foundation For Medical Education And Research Compositions and methods for tissue specific gene regulation therapy
WO2003037260A2 (en) 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
AU2003228751A1 (en) 2002-05-01 2003-11-17 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
US20060045910A1 (en) 2004-09-02 2006-03-02 Ehringer William D Preserved fusogenic vesicles
GB0426641D0 (en) 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
US8034331B2 (en) 2005-01-20 2011-10-11 Agency For Science, Technology And Research Method of delivery of nucleic acids to peripheral neurons
ATE461710T1 (de) 2005-04-25 2010-04-15 Merial Ltd Nipah-virus-impfstoffe
WO2007005244A1 (en) 2005-07-05 2007-01-11 The Regents Of The University Of California Henipavirus receptor and uses thereof
WO2008115199A2 (en) 2006-08-18 2008-09-25 The University Of North Carolina At Chapel Hill Chimeric virus vaccines
EP1975239A1 (en) * 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
WO2008071959A1 (en) 2006-12-12 2008-06-19 Oxford Biomedica (Uk) Limited Lentiviral vectors comprising micrornas
EP4154903A1 (en) 2008-04-22 2023-03-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
JP2012508233A (ja) 2008-11-07 2012-04-05 チルドレンズ ホスピタル メディカル センター 膜貫通薬物送達システムへの適用のためのサポシンｃ、並びに関連のタンパク質及びペプチドの融合性
MX2012001075A (es) 2009-07-24 2012-05-22 Immune Design Corp Vectores lentivirales pseudotipificados con una glicoproteina de envoltura de virus sindbis.
JP5878126B2 (ja) 2009-11-13 2016-03-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 工学操作された微小胞を用いての直接的なタンパク質の送達
EP2476754A1 (en) 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
JP2014512409A (ja) 2011-04-28 2014-05-22 エスティーシー． ユーエヌエム 標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその使用方法
ES2963147T3 (es) * 2011-05-13 2024-03-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
SG11201401499XA (en) * 2011-10-14 2014-09-26 Stc Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2615176A1 (en) * 2012-01-11 2013-07-17 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Novel pseudotyped lentiviral particles and their use in the in vitro targeted transduction of undifferentiated pluripotent human embryonic stem cells and induced pluripotent stem cells
US9486539B2 (en) 2012-03-26 2016-11-08 The Regents Of The University Of California Nipah virus envelope pseudotyped lentiviruses and methods of their use
CN105051192B (zh) 2012-11-13 2020-04-17 科迪艾克生物科学公司 治疗剂的递送
EP3889182B1 (en) 2013-03-13 2024-05-22 Imaginab, Inc. Antigen binding constructs to cd8
GB201313249D0 (en) 2013-07-25 2013-09-11 Isis Innovation Method
DK3096741T3 (da) 2014-01-21 2020-09-28 Anjarium Biosciences Ag Fremgangsmåde til fremstillingen af hybridosomer
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
AU2016217906B2 (en) * 2015-02-11 2021-09-02 Alma Mater Studiorum Universita' Di Bologna Retargeted herpesvirus with a glycoprotein H fusion
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
US10729789B2 (en) 2016-03-01 2020-08-04 University Of Virginia Patent Foundation Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
EP3430136A2 (en) * 2016-03-19 2019-01-23 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulated expansion thereof
WO2017173034A1 (en) 2016-03-30 2017-10-05 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
AU2017276727B2 (en) 2016-06-09 2023-10-05 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein H for propagation in a cell
EP3472318B1 (en) 2016-07-08 2023-09-06 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
CN110073000A (zh) 2016-07-26 2019-07-30 森迪生物科学公司 遗传擦除子
CA3047140A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Constructs for expression of therapeutic proteins in target cells
EP3622079B1 (en) 2017-05-08 2025-08-20 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
CA3083286A1 (en) 2017-12-07 2019-06-13 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
CA3091478A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
JP7568513B2 (ja) 2018-05-15 2024-10-16 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド フソソーム組成物およびその使用
KR20210043574A (ko) 2018-07-09 2021-04-21 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소좀 조성물 및 이의 용도
AU2019380517A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
KR20210131991A (ko) 2018-11-14 2021-11-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 구획-특이적 카고 전달을 위한 조성물 및 방법
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
AU2019378881A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for CNS delivery

Also Published As

Publication number Publication date
AU2020203813A1 (en) 2020-07-02
JP2024028379A (ja) 2024-03-04
US20190144885A1 (en) 2019-05-16
JP2022087199A (ja) 2022-06-09
EP3445862B1 (en) 2023-10-25
JP2019514373A (ja) 2019-06-06
EP4151737A1 (en) 2023-03-22
ZA201807161B (en) 2019-06-26
BR112018071584A2 (pt) 2019-03-12
EA201892369A1 (ru) 2019-05-31
JP7754959B2 (ja) 2025-10-15
WO2017182585A1 (en) 2017-10-26
JP7412885B2 (ja) 2024-01-15
AU2023258359A1 (en) 2024-01-18
JP2025188096A (ja) 2025-12-25
NZ747658A (en) 2024-04-26
JP7577039B2 (ja) 2024-11-01
AU2020203813B2 (en) 2023-08-03
EP4151737A8 (en) 2023-12-20
EP3235908A1 (en) 2017-10-25
IL262458B2 (en) 2025-11-01
AU2017253364B2 (en) 2020-07-02
ES2961976T3 (es) 2024-03-14
US20230348934A1 (en) 2023-11-02
IL321626A (en) 2025-08-01
MX2023006961A (es) 2023-06-23
JP2021184767A (ja) 2021-12-09
KR20190046713A (ko) 2019-05-07
CN117126817A (zh) 2023-11-28
AU2017253364A1 (en) 2018-11-15
IL262458B1 (en) 2025-07-01
SG11201809164TA (en) 2018-11-29
KR20250035028A (ko) 2025-03-11
CA3021549A1 (en) 2017-10-26
US11608509B2 (en) 2023-03-21
IL262458A (en) 2018-12-31
EP3445862A1 (en) 2019-02-27
CN109642243A (zh) 2019-04-16
KR102775926B1 (ko) 2025-03-04

Similar Documents

Publication Publication Date Title
MX2018012814A (es) Métodos para modular selectivamente la actividad de distintos sub-tipos de células.
BR112019010565A2 (pt) aplicação viral de neoantígenos
CO2019013609A2 (es) Vectores de neoantígeno de alfavirus
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
AR122050A2 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
MX2020004578A (es) Composiciones de casz y metodos de uso.
CY1121953T1 (el) Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων
MX2021014525A (es) Adenovirus modificados.
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112016020287A2 (pt) células resistentes a vírus e usos das mesmas
MX2017010553A (es) Vector.
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
MX395524B (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
WO2015177098A3 (en) Coated oncolytic adenoviruses for cancer vaccines
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
BR112014027239A2 (pt) peptídeo, método de identificação de peptídeos, método para o tratamento de câncer, nucleotídeo, vetor, uso de um peptídeo e invenção
MX2018000845A (es) Vector vírico orf recombinante.
MX2019007924A (es) Vacunas contra la influenza.
ES2689797T3 (es) Vacuna de virus Sendai modificado y vector para la obtención de imágenes
BR112019007343A2 (pt) sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina
CO2021001290A2 (es) Compuestos peptídicos y usos terapéuticos de los mismos
AR104967A1 (es) Polinucleótido aislado, vector recombinante, adenovirus recombinante y composición que lo comprenden y su uso para preparar un medicamento
MY185846A (en) Oncolytic adenovirus encoding a b7 protein